Q Biomed (QBIO) Stock Price, News & Analysis

Company Overview

Q BioMed, Inc. is a biomedical acceleration company that identifies, acquires and advances early‐stage therapeutic assets toward partnering and out‐licensing opportunities. The company focuses on assets that have demonstrated mechanistic proof of concept but require additional development expertise or capital to reach critical value inflection points. Q BioMed’s business model emphasizes risk mitigation by in-licensing under-developed candidates and shepherding them through preclinical and early clinical development milestones before transitioning them to strategic partners.

The company’s pipeline encompasses a range of small molecules, biologics and device candidates in therapeutic areas such as acute ocular pain and chronic joint disorders. By applying formulation and delivery technologies, Q BioMed aims to improve pharmacokinetic profiles and patient compliance for compounds that may otherwise face development hurdles. Its development programs leverage in-house expertise to generate non-dilutive value through licensing events at defined stages of program maturation.

Q BioMed maintains a lean organizational structure and collaborates with contract research organizations, manufacturing partners and academic institutions to execute its development programs. This partnership‐driven model allows the company to capitalize on external capabilities while retaining strategic control over program direction and milestone planning. Through carefully structured license agreements, Q BioMed seeks to maximize long-term returns on its portfolio by aligning incentive structures with those of its partners.

Headquartered in Rochester, New York, Q BioMed serves global markets through its network of international collaborators. The company’s approach to biomedical acceleration is designed to address the high cost and time associated with bringing novel therapies to market, with a focus on generating data packages that attract commercial partners and optimize shareholder value.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: 8,750 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

QBIO Stock Analysis - Frequently Asked Questions

How were Q Biomed's earnings last quarter?

Q Biomed Inc. (OTCMKTS:QBIO) announced its earnings results on Wednesday, July, 14th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.12) by $0.04. The firm earned $0.05 million during the quarter.

How do I buy shares of Q Biomed?

Shares of QBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Q Biomed own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Q Biomed investors own include Intel (INTC), Washington Trust Bancorp (WASH), Cisco Systems (CSCO), Nokia (NOK), NVIDIA (NVDA), Micron Technology (MU) and NewAge (NBEV).

Company Calendar

• Last Earnings: 7/14/2021
• Today: 9/20/2025
• Fiscal Year End: 11/30/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Medical Services
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:QBIO
• Previous Symbol: NASDAQ:QBIO
• CIK: 1596062
• Web: www.qbiomed.com
• Phone: (646) 889-2226
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $280 thousand
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: 2.40